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Abstract
Several associations between non-genetic biomarkers and colorectal cancer (CRC) 
risk have been detected, but the strength of evidence and the direction of associa-
tions are not confirmed. We aimed to evaluate the evidence of these associations and 
integrate results from different approaches to assess causal inference. We searched 
Medline and Embase for meta-analyses of observational studies, meta-analyses 
of randomized clinical trials (RCTs), and Mendelian randomization (MR) studies 
measuring the associations between non-genetic biomarkers and CRC risk and meta-
analyses of RCTs on supplementary micronutrients. We repeated the meta-analyses 
using random-effects models and categorized the evidence based on predefined crite-
ria. We described each MR study and evaluated their credibility. Seventy-two meta-
analyses of observational studies and 18 MR studies on non-genetic biomarkers and 
six meta-analyses of RCTs on micronutrient intake and CRC risk considering 65, 
42, and five unique associations, respectively, were identified. No meta-analyses of 
RCTs on blood level biomarkers have been found. None of the associations were 
classified as convincing or highly suggestive, three were classified as suggestive, 
and 26 were classified as weak. For three biomarkers explored in MR studies, there 
was evidence of causality and seven were classified as likely noncausal. For the first 
time, results from both observational and MR studies were integrated by triangulat-
ing the evidence for a wide variety of non-genetic biomarkers and CRC risk. At 
blood level, lower vitamin D, higher homeostatic model assessment-insulin resist-
ance, and human papillomavirus infection were associated with higher CRC risk 
while increased linoleic acid and oleic acid and decreased arachidonic acid were 
likely causally associated with lower CRC risk. No association was found convinc-
ing in both study types.
K E Y W O R D S
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1 |  INTRODUCTION
Colorectal cancer (CRC) is the third most common can-
cer, and the second leading cause of cancer death globally.1 
More than 1.8 million new cases and 881 000 deaths were 
estimated to have occurred in 2018.1 Furthermore, although 
there are stable or descending trends in many high-income 
countries, their age-specific incidence and mortality rates re-
main among the highest in the world, especially the incidence 
among young adults.2,3
A biomarker is defined as a cellular, biochemical, or mo-
lecular alteration that can be measured and is used to objec-
tively evaluate normal biological or pathological processes.4 
Different types of biomarkers have been investigated in re-
lation to CRC risk. Environmental factors play an important 
role in the etiology of CRC through modulating differenti-
ation, apoptosis, angiogenesis, proliferation, and immune 
processes against endothelial cells.5 Identifying specific bio-
markers related to CRC risk is important for understanding 
cancer etiology and mechanisms of progression as well as 
early detection and cancer screening that could consequently 
reduce CRC mortality. The aims of this review were: (a) to 
identify meta-analyses of observational studies, meta-anal-
yses of randomized clinical trials (RCTs), and Mendelian 
randomization (MR) studies on non-genetic biomarkers 
and CRC risk; (b) to evaluate the observed associations and 
classify the level of credibility of the evidence; and (c) to 
integrate the evidence across different approaches using an 
evidence triangulation framework. Genetic risk factors have 
been recently explored in a number of field synopses6,54 and 
meta-analyses of genome wide association studies,8,9and are 
not considered in this work.
2 |  METHODS
2.1 | Search strategy and eligibility criteria
Two reviewers searched Medline and Embase to identify 
meta-analyses of observational studies (1 January 2010 to 14 
June 2019), meta-analyses of RCTs (1 January 2010 to 14 
June 2019), and MR studies (up to 20 June 2019) investi-
gating the association between non-genetic biomarkers and 
CRC risk. As no meta-analyses of RCTs on non-genetic bio-
markers were identified, we included meta-analyses of RCTs 
(1 January 2010 to 14 June 2019) on micronutrient intake 
as proxies of micronutrient blood levels. Systematic reviews 
without meta-analyses were excluded. Meta-analyses of ob-
servational studies on non-genetic biomarkers and CRC risk 
published before 2010 had been previously reviewed in a 
published umbrella review.10 The main results of these stud-
ies were extracted from the published umbrella review and 
were further evaluated and assessed together with additional 
studies published from 2010 onwards. A parallel review was 
conducted by a third reviewer. In the case of any discrepancy 
in assessments, a final decision was made after discussion. 
The details of all search strategies are provided in Table S1. 
We first reviewed the title and abstract of the identified stud-
ies and then evaluated the full text of all potential eligible 
studies. We manually checked the references of all retrieved 
articles to include any missed relevant studies. Studies in-
vestigating the associations between genetic or non-genetic 
biomarkers and CRC screening, diagnosis, survival, and 
prognosis were excluded.
2.2 | Data extraction
One investigator extracted information from each eligible 
study and two other investigators checked the extracted data. 
A fourth investigator was involved to judge any discrepancies. 
For meta-analyses of observational studies, we extracted the 
first author, year of publication, number of studies considered, 
epidemiological study design, biomarker details, outcome, and 
study population. We also recorded the study-specific relative 
risk estimates (risk ratio, odds ratio, hazard ratio, standard-
ized mean difference, weighted mean difference, standard-
ized correlation coefficient), details of the applied statistical 
models, correspondent confidence intervals, and number of 
cases and participants. For meta-analyses of RCTs on micro-
nutrient intake, we further extracted the dose and duration of 
supplementation, number of events, and type of intervention 
in the control group. For MR studies, we extracted: the ex-
posure, study design, effect estimate unit, sample size, popu-
lation ethnicity for both exposure and outcome groups, main 
MR estimate and any sensitivity analyses for the associations 
of genetic instruments with the exposure and outcome, total 
variance level explained by the genetic instrument assuming 
an additive model (R2), and the approximate statistical power 
(where presented).
2.3 | Statistical analysis
For the meta-analyses of observational studies, we re-esti-
mated the summary effect size and its confidence interval. 
As the most commonly used DerSimonian and Laird (DL) 
estimator tends to underestimate the 95% CI when less than 
10 studies are included,11 we used the Hartung-Knapp-Sidik-
Jonkman (HKSJ) method as the main random effect esti-
mator.12 The HKSJ estimator consistently results in more 
adequate error rates even when the number of studies is 
small or between studies heterogeneity exists.12,13 The meta-
analysis P value threshold was set at .05. The Paule-Mandel 
(PM) estimator could give an accurate result when between-
study heterogeneity is large but the number of studies is not 
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small.13 Therefore, DL14 and PM15 methods were also ap-
plied as sensitivity analyses. We quantified the heterogene-
ity of each meta-analysis by calculating the I2 value and its 
95% prediction interval.16,17 We used the Egger regression 
asymmetry test to estimate any small study effect.18 The 
excess significance test was performed to evaluate whether 
the observed number of studies with positive results was sig-
nificantly greater than the expected number by using a chi-
square test.19 For both the small study effect and the excess 
significance test, we used P < .1 as the threshold.
Stata version 14.0 and “metafor” package20
in R 3.5.1 were used for statistical analysis. Two-tailed P 
values were used.
2.4 | Credibility assessment
If there were more than one meta-analysis of observational 
studies or more than one MR study investigating the asso-
ciation between the same biomarker and CRC risk, we com-
pared the direction, level of statistical significance (P ≤ .05), 
and effect size. The most recent meta-analysis with the larg-
est number of prospective studies was retained for further 
analysis. The most recent MR study (unless a previous MR 
study employed a stronger genetic instrument and/ or had a 
larger sample size at the outcome arm) was retained for fur-
ther comparison.
If we identified meta-analyses of observational studies and 
MR studies investigating the same biomarker, we compared 
the direction and level of statistical significance (P ≤  .05). 
All associations explored in meta-analyses of observational 
studies and/ or MR studies are presented in an evidence tri-
angulation plot.21,22
We categorized the evidence from meta-analyses of obser-
vational studies for each eligible biomarker in four categories 
according to previously defined criteria that considered the 
quantified evidence, statistical significance, heterogeneity, 
small study effect, excess significance bias, and prediction 
interval (convincing or class I, highly suggestive or class II, 
suggestive or class III, weak or class IV, and no association).23 
The evidence classification criteria are described in Table 1. 
For each convincing or highly suggestive association, we re-
checked the eligibility for each individual study, re-evaluated 
the accuracy of extracted data, and reassessed the evidence 
after restricting the analysis to prospective cohort studies.
Associations detected from MR studies were catego-
rized into “Evidence of causality,” “Likely noncausal,” and 
“Unknown” by considering statistical significance (P < .05), 
pre-estimated power (Power  ≥  0.8 regarded as sufficient), 
and evidence of bias due to directional pleiotropy (Table 1).
3 |  RESULTS
The literature search returned 9227 hits for the meta-analyses 
of observational studies and RCTs, and returned 75 hits for 
MR studies. After applying the predefined inclusion and ex-
clusion criteria, 72 meta-analyses of observational studies, 18 
MR studies, and six meta-analyses of RCTs on supplemen-
tary micronutrients were identified (Figure 1).
Evidence category Criteria
Meta-analyses of observational studies
Convincing (class I) P < .001; >1000 cases; P < .05 in the largest study
A 95% PI that excluded the null; I2 < 50%





P < .05 in the largest study
Suggestive (class III) P < .001; >1000 cases
Weak (class IV) P < .05
No association P ≥ .05
Mendelian randomization study
Evidence of causality P < .05 or threshold set up by individual study due to multiple testing; 
evaluated pleiotropy but have no evidence of directional pleiotropy.
Likely noncausal P > .05 or threshold setup by individual study due to multiple testing; 
Power ≥0.8; consistent evidence between main MR analysis and 
sensitivity analyses; evaluated pleiotropy but have no evidence of 
directional pleiotropy
Unknown Studies that cannot be classified as either “Evidence of causality” or 
“Likely noncausal”
Abbreviation: PI: prediction interval.
T A B L E  1  Credibility assessment 
criteria for meta-analyses of observational 
studies and Mendelian randomization 
studies
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F I G U R E  1  A, PRISMA flow diagram illustrating the study screening and selection process for meta-analyses of observational studies and 
meta-analyses of randomized clinical trials (performed on 14/06/2019). B, PRISMA flow diagram illustrating the study screening and selection 
process for Mendelian randomization studies (performed on 20/06/2019)
Studies identified through database searches
MEDLINE via OVID (n=3586)
EMBASE via OVID (n=8780)
(Total n = 12366) [01/01/2010-14/06/2019]
Duplicates removed
(n = 3139)






Biomarkers and CRC diagnosis, treatment 
and prognosis (n = 12)
Did not do quantitative analysis (n = 50)
Not none-genetic biomarkers (n = 35)
Not in English (n = 6)
Not in CRC (n = 8)
Did not find full text paper (n = 1)
Biomarkers and CRA risk (n=15)
Meta-analysis of in-vivo study (n=2)





Included from reference review
(n=1)
Included from {Tsilidis, K.K., et al.}
(n=5) [Before 01/01/2010]
Abstracts screened (n = 1236)
Full-text articles assessed for eligibility:
Meta-analyses of observational studies and 
RCTs (n = 195)
Supplementary meta-analyses of RCTs (n = 28)





Included both RCT and observational 
studies for supplementary meta-analyses of 
RCTs (n = 1)
Component studies of meta-analyses were 
on different nutrients and CRC risk (n = 2)
Not meta-analysis of RCTs (n = 11)
Not in CRC (n = 6)
Not full text paper (n = 2)
Studies identified through database searches
MEDLINE via OVID (n=40)
EMBASE via OVID (n=73)
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F I G U R E  2  Evidence triangulation bubble plot for biomarkers detected from meta-analyses of observational studies and MR studies. The 
bubble size of meta-analyses of observational studies represents the number of cases and the bubble size of MR studies represents the number of 
CRC cases divided by 5. AA, arachidonic acid; Adiponectin1, Adiponectin in European and United State population; Adiponectin2, Adiponectin in 
European population only; ALA, α-Linolenic acid; B.b, bifidobacterium; Blood-A/B/AB/O, Blood group A/B/AB/O; CD26, dipeptidyl peptidase 
IV; CRP, C-reactive protein; DGLA, dihomo-γ-linolenic acid; DHA, Docosahexaenoic acid; DPA, Docosapentaenoic acid; E.b, enterobacteriaceae; 
E.c, escherichia coli; EPA, Eicosapentaenoic acid; F.b, faecalibacterium prausnitzii; F-glucose, fasting glucose; F-insulin, fasting insulin; F.n, F. 
nucleatum; F-proinsulin, fasting proinsulin; GDF-15, Growth differentiation factor 15; HbA1C, glycated hemoglobin; HCI, human cytomegalovirus 
infection; Hcy, homocysteine; HDL, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; HPV, 
Human papillomavirus; H.pylori, helicobacter pylori; IGE, serum immunoglobulin E; IGF-1/2, insulin-like growth factor 1/2; IGFBP 1/2/3, Insulin-
like growth factor-binding protein 1/2/3; IL-6, interleukin 6; LA, linoleic acid; L.b, lactobacillus; LDL, low-density lipoprotein cholesterol; MA 
only, Biomarkers only detected in meta-analyses of observational studies; MMP7, matrix metalloproteinase-7; MR only, Biomarkers only detected 
in MR studies; MUFA, mono-unsaturated fatty acids; n-3 PUFA, long chain n-3 polyunsaturated fatty acid; n-6 PUFA, n-6 polyunsaturated fatty 
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3.1 | Meta-analyses of observational studies
A total of 145 effect estimates for 65 unique biomarkers were 
extracted from the 72 included meta-analyses of observational 
studies (Table S4). The median number of included compo-
nent studies for each meta-analysis was 7 (range: 2-31). The 
median number of cases was 1170 (range: 37-62 814) and 
of participants was 4240 (range: 76-7 725 310). More than 
one meta-analysis of observational studies was identified 
for 20 biomarkers (Table S6): helicobacter pylori infection 
(H. pylori, n  =  9), human papillomavirus infection (HPV, 
n = 8), blood levels of folate (n = 6), blood levels of vita-
min B12 (n = 5), blood levels of vitamin B6 (n = 5), blood 
levels of vitamin B2 (n  =  2), blood levels of 25-hydroxy-
vitamin D (n = 10), C-reactive protein (CRP, n = 3), inter-
leukin-6 (IL-6, n  =  2), fasting glucose (n  =  6), C peptide 
(n = 3), insulin-like growth factor-1 (IGF-1; n = 3), IGF-2 
(n = 2), insulin-like growth factor-binding protein 3 (IGFBP-
3, n = 2), triglycerides (n = 3), high-density lipoprotein cho-
lesterol (HDL-cholesterol, n = 2), adiponectin (n = 7), leptin 
(n = 4), telomere length (n = 3), and homocysteine (n = 3). 
Seventeen of the 20 (85%) overlapping meta-analyses agreed 
on the direction of the effect estimate, 12 of these 17 agreed 
on the level of statistical significance, and 10 of these 12 as-
sociations were statistically significant (Table S6).
After removing the overlapping meta-analyses, a total 
of 65 unique biomarkers were retained for further statistical 
analysis (Figure 3; Tables S2 and S7). We categorized the 
biomarkers into seven categories: fatty acid/lipid metabo-
lism biomarkers (n = 14), micronutrients (n = 10), infectious 
agents (n = 13), inflammatory markers (n = 2), insulin-re-
lated biomarkers (n = 10), protein/amino acids (n = 10), and 
other biomarkers (n = 6).
A total of 29 associations among the 65 non-overlapping 
meta-analyses of observational studies (45%) were statisti-
cally significant (P < .05) by using the HKSJ meta-analysis 
estimator (Table S2; Figures  2 and 3). Sensitivity analyses 
using the DL and PM estimator are presented in Table S7. 
Eight and five associations were upgraded when using DL 
estimator or the PM estimator instead of the HKSJ estimator, 
respectively. Sixteen of the 29 significant biomarkers were 
associated with increased CRC risk. In these 29 statistically 
significant associations, 7 (24%) had P < .001, 24 (83%) had 
a 95% prediction interval that excluded null, 14 (48%) had 
more than 1000 cases, 13 (45%) had no obvious large hetero-
geneity (I2 < 50%), 20 (69%) were not subject to small-study 
effect or excess significance bias (Table S2). After applying 
the credibility criteria, one biomarker (fasting glucose [RR 
(95% CI): 1.27 (1.11, 1.45)]) was classified as highly sugges-
tive and three biomarkers were classified as suggestive (ho-
meostatic model assessment-insulin resistance [HOMA-IR; 
RR (95% CI): 1.56(1.22, 1.98)], 25-hydroxyvitamin D 
[RR (95% CI): 0.67(0.54, 0.83)], and HPV [RR (95% CI): 
3.52(1.77, 7.00)]). For the associations classified as “highly 
suggestive,” we checked the eligibility of each component 
study, evaluated the accuracy of the extracted data and re-
assessed the evidence after restricting the analysis to only 
including prospective studies. The evidence of association 
between fasting glucose and CRC risk was downgraded to 
“weak.”
We identified six meta-analyses of RCTs on associations 
between supplementary micronutrients and CRC risk, but 
none of them reported a statistically significant association 
(Table S8).
3.2 | Mendelian randomization studies
Sixty-six MR studies were extracted from 18 publications 
(Table S5). The median number of cases for the outcome arm 
of each included MR study was 13 012 (range: 329-30 480), 
the median number of participants was 36 137 (range: 727-
382 756), and the median variance explained by each genetic 
instrument was 2.92% (range: 0.3%-60.4%). Eight (12%) 
MR studies had enough power (≥0.8) to detect a statistically 
significant effect estimate. Overlapping MR studies were 
detected for 14 biomarkers (Table S6). Nine of the 14 MR 
studies agreed on the direction of the effect size and eight 
of which agreed on the level of statistical significance: over-
lapping MR studies for plasma arachidonic acid (n = 2) and 
plasma linoleic acid (n = 2) agreed on the direction of ef-
fect size and the effect size estimates were statistically sig-
nificant; overlapping MR studies for adiponectin (n  =  3), 
fetuin-A (n = 2), docosapentaenoic acid (DPA, n = 2), do-
cosahexaenoic acid (DHA; n  =  2), low-density lipoprotein 
cholesterol (LDL-cholesterol, n  =  3), and telomere length 
(n = 2) were concordant in the direction, but the effect size 
estimates were not statistically significant; overlapping MR 
studies for total cholesterol (n = 2) agreed on the direction 
but not on the level of statistical significance; MR studies for 
blood levels of 25-hydroxyvitamin D (n = 8), eicosapentae-
noic acid (EPA; n = 2), triglyceride (n = 3), HDL-cholesterol 
(n = 3), and CRP (n = 3) neither agreed on direction nor on 
statistical significance.
The biomarkers of the 66 MR analyses were categorized 
into six categories: micronutrients (n = 17), fatty acid/lipid me-
tabolism biomarkers (n = 30), inflammatory markers (n = 4), 
protein/amino acid (n = 9), insulin-related markers (n = 4), and 
other biomarkers (n = 2) (Table S5). Nine (14%) biomarkers 
(stearic acid, arachidonic acid [n = 2], linoleic acid [n = 2], 
oleic acid, palmitoleic acid, total cholesterol, and CRP) re-
ported statistically significant associations (at P < .05 or at a 
study specified threshold due to multiple testing). After remov-
ing the overlapping MR studies, 42 biomarkers were retained 
for analysis (Table S3; Figure 3), three biomarkers (arachidonic 
acid [OR (95% CI): 1.05 (1.03, 1.07)], linoleic acid [OR (95% 
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F I G U R E  3  A, Forest plot for evidence of associations between non-genetic biomarkers and CRC risk from meta-analyses of observational 
studies (metric: odds ratio and risk ratio). B, Forest plot for evidence of associations between non-genetic biomarkers and CRC risk from 
meta-analyses of observational studies (metric: standardized mean difference). C, Forest plot for evidence of associations between non-genetic 
biomarkers and CRC risk from MR studies (metric: odds ratio). *, total number of participants for exposure and CRC Genome-wide association 
studies; AA, arachidonic acid; ALA, α-Linolenic acid; CD26, dipeptidyl peptidase IV; CI, confidence interval, results of meta-analyses were 
analyzed by using Hartung-Knapp-Sidik-Jonkman method; CRC, colorectal cancer; CRP, C-reactive protein; DGLA, dihomo-γ-linolenic acid; 
DHA, Docosahexaenoic acid; DPA, Docosapentaenoic acid; EPA, Eicosapentaenoic acid; GDF-15, Growth differentiation factor 15; GRS, genetic 
risk score; H.pylori, Helicobacter pylori; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model 
assessment-insulin resistance; HPV, Human papillomavirus; IGF 1/2, Insulin-like growth factor 1/2; IGFBP 1/2/3, Insulin-like growth factor-
binding protein 1/2/3; IL-6, Interleukin 6; LA, linoleic acid; LC n-3 PUFA, long chain n-3 polyunsaturated fatty acid; LDL, low-density lipoprotein 
cholesterol; MMP7, matrix metalloproteinase-7; OR, odds ratio; RR, risk ratio; SMD, standardized mean difference; SNP, Single-Nucleotide 
Polymorphism
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CI): 0.95 (0.93, 0.97)], and oleic acid [OR (95% CI): 0.77 (0.65, 
0.92)]) with statistically significant effect estimates and with-
out evidence of biological pleiotropy were classified as having 
“Evidence of causality”. Seven MR studies were categorized as 
“Likely noncausal,” since these studies had enough statistical 
power and no evidence of biological pleiotropy, but they were 
statistically nonsignificant (LDL–cholesterol, omega-6 polyun-
saturated fatty acids, total cholesterol, selenium, vitamin B12, 
telomere length, adiponectin).
Twenty non-genetic biomarkers were analyzed in both 
meta-analyses of observational studies and MR studies (Table 
S6; Figure 2). Ten of the 20 biomarkers (25-hydroxyvitamin 
D, selenium, vitamin E, total cholesterol, LDL-cholesterol, 
CRP, fasting glucose, glycated hemoglobin [HbA1C], ad-
iponectin, telomere length) agreed on the direction of the 
effect size, six (selenium, vitamin E, total cholesterol, LDL-
cholesterol, HbA1C, telomere length) of which agreed on 
the level of statistical significance (not significant). One 
biomarker (25-hydroxyvitamin D) was analyzed by three dif-
ferent study types (meta-analysis of observational study, MR 
studies, and meta-analysis of RCTs on supplementary vita-
min D), but only the meta-analyses of observational studies 
reported a statistically significant association.
4 |  DISCUSSION
In this study, a comprehensive overview of associations 
between a wide range of non-genetic biomarkers and CRC 
risk was conducted by triangulating evidence from meta-
analyses of observational studies, MR studies, and meta-
analyses of RCTs. The non-genetic biomarkers for CRC 
risk which were studied covered seven categories and CRC 
risk was associated with 34 examined biomarkers. There 
is a gap of meta-analyses of RCTs or even individual 
RCTs on biomarkers of CRC risk and these were only ex-
amined in observational studies. We, therefore, included 
meta-analyses of RCTs of supplementary micronutrients 
as proxies.
4.1 | Meta-analyses of observational studies
Twenty-nine biomarkers were associated with CRC risk at 
P  <  .05 from meta-analyses of observational studies, but 
none of these association was classified as convincing or 
highly suggestive. Of these 29 statistically significant asso-
ciations, three (25-hydroxyvitamin D, HPV, and HOMA-IR 
F I G U R E  3  Continued
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[HOMA-IR = glucose ×insulin/405]) were classified as sug-
gestive and 26 as weak.
The association between vitamin D concentration and 
CRC risk was classified as suggestive (Class III) and indi-
cated that a higher blood concentration of vitamin D was 
associated with a 33% decrease in CRC risk. This result was 
consistent among all eight overlapping meta-analyses.24,25 
Experimental studies based on mouse models have indicated 
that the potent steroid hormone Calcitriol (the active form of 
vitamin D) may play a protective role against CRC through 
F I G U R E  3  Continued
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the regulation of proliferation, pro-differentiation, pro-apop-
tosis, anti-angiogenesis, and immune modulation.26 However, 
results from RCTs do not support a causal role between sup-
plementary vitamin D (from 800 IU/d to 1000 IU/d with or 
without calcium supplementation for 1-7  years) and CRC 
risk (Table S8). Similarly, the eight overlapping MR studies 
included in this review did not identify a causal association 
between blood level of vitamin D and CRC risk (Table S6). 
Therefore, currently, there is no evidence for a clear causal 
role of vitamin D on CRC risk. It is also possible that the 
nonsignificant results from RCTs and MR studies are due to 
the distinct limitations of these two study designs, such as 
limited follow-up time, insufficient supplementary dose, and 
contamination of controls for RCTs and collider bias, limited 
power, and potential pleiotropy for MR studies.
A statistically significant association between diabetes 
and CRC risk has been previously identified by an umbrella 
review published in 2014.27 In the current study, among 
the insulin-related biomarkers, HOMA-IR (a method to 
quantify insulin resistance based on the blood concentra-
tion of glucose and insulin) showed suggestive evidence 
(Class III) for an association with a higher risk of CRC. 
Similarly, IGF-1 and fasting glucose had weak evidence for 
an association with CRC risk. Elevated glucose and insulin 
levels may increase CRC risk through their pro-prolifera-
tion, pro-angiogenesis, and apoptosis inhabitation effects 
against tumor cell.28 For example, exposure to high glucose 
could lead to increased generation of reactive oxygen inter-
mediates and subsequently could induce apoptosis of en-
dothelial cells.29 In addition, hyperglycemia could increase 
the concentration of circulating inflammatory cytokines 
leading to chronic inflammation, which has been suggested 
to relate to tumor generation.30,31 However, in this review, 
we did not find evidence of an association between in-
flammatory markers and CRC risk. The tumor cell growth 
simulated by high concentrations of insulin through the ac-
tivation of IGF-1, and the possible protective effect of the 
use of metformin (found in a meta-analysis including 12 
cohort studies, seven case-controls studies, and one RCT)32 
on CRC development further supports the insulin-CRC as-
sociation. In conclusion, preclinical and epidemiological 
evidence supports an association between insulin-related 
biomarkers on CRC risk, but causality is not supported by 
MR studies. We should note that diabetes shares many risk 
factors with CRC, which could explain the observed asso-
ciations from observational studies.
Interestingly, seven different types of pathogenic micro-
organisms were found to be related to CRC risk, but most 
of the evidence was classified as weak due to small number 
of cases. Only HPV showed a suggestive association with 
CRC risk. HPV is a non-enveloped double-stranded DNA 
virus with more than 170 types. Twelve of these types are 
considered as causal risk factors for cervical cancer (known 
as high-risk HPV types) by IARC Monographs.33,34 In ad-
dition, HPV 16, HPV 18, and HPV 33 have commonly been 
found in CRC cases.35,36,37 The potential mechanisms of 
HPV on colorectal carcinogenesis include viral integration 
in host cells and expression of E6 and E7 oncoproteins; 
however, evidences of whether HPV infection is truly in-
volved in colorectal carcinogenesis are still not convinc-
ing.38 Furthermore, this finding should be interpreted with 
caution, since the HPV-CRC association was analyzed 
without stratifying by HPV type. Meanwhile, all the in-
cluded meta-analyses synthesized retrospective observa-
tional studies; therefore, the observed associations could 
be due to reverse causality.
Overall, meta-analyses of observational studies indi-
cated weak associations between non-genetic biomarkers 
and CRC risk. In this review, only seven of 65 associations 
fulfilled the P-value threshold of convincing evidence, and 
of these three were based on evidence from less than 1000 
cases, three did not have a statistically significant P-value 
for their largest component study and for one there was ev-
idence of small study effect bias and excess significance 
bias. Despite weak evidence after applying the predefined 
credibility criteria, we cannot ignore the clinical impor-
tance of these associations. Notably, most (85%) of the 
overlapping studies agreed on the direction of effect esti-
mate and over half (60%) agreed on both the direction and 
statistical significance.
4.2 | Mendelian randomization studies
Almost half of the biomarkers identified from MR studies 
were biomarkers of fatty acid/lipid metabolism. Most of the 
detected MR studies had insufficient power (<0.8). There 
were nine MR studies that reported statistically significant 
results. After retaining the largest MR study for each bio-
marker and applying the predefined assessment criteria, we 
found evidence that high blood levels of linoleic acid and 
oleic acid and low blood levels of arachidonic acid were as-
sociated with low CRC risk. Conversely, LDL-cholesterol, 
omega-6 polyunsaturated fatty acids (n-6 PUFAs), total cho-
lesterol, selenium, vitamin B12, telomere length, and adi-
ponectin were not found to be associated with CRC risk.
n-3 and n-6 PUFAs are essential fatty acids and cannot be 
produced in the human body.39 The beneficial effects of high 
levels of n-3 PUFAs and low levels of n-6 PUFAs on CRC 
risk reduction remain debatable. In this review, a weak pro-
tective effect of n-3 PUFAs on CRC risk was detected from 
meta-analyses of prospective observational studies while MR 
analyses did not show any evidence of causality. Similarly, 
RCTs did not report any association between supplementa-
tion of n-3 fatty acids (combination of EPA and DHA) and 
CRC incidence.40,41 Arachidonic acid is an n-6 PUFA, which 
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in this review is suggested to causally increase the risk of 
CRC. The potential mechanism is that arachidonic acid can 
regulate CRC development through the inhibition of cycloo-
xygenase (COX)/lipoxygenase (LOX) and has a competitive 
relation to DPA in terms of COX enzyme activity.39,42 Oleic 
acid and linoleic acid are two of the main components of olive 
oil and have been examined as protective biomarkers for CRC 
risk by MR studies in this review. These findings, along with 
evidence from a literature review on olive oil intake and a co-
hort study on Mediterranean diet,43,44 support the beneficial 
effect of oleic acid and linoleic acid on CRC risk. However, 
the genetic instruments for the two n-6 PUFAs are similar, 
which indicate the possibility that arachidonic acid and lin-
oleic acid may share the same pathway to influence CRC risk 
and represent vertical pleiotropy.
Overall, we found that there was either lack of evidence 
or that the credibility of evidence varied across the three dif-
ferent study designs. For instance, evidence detected from 
meta-analyses of observational studies was not confirmed 
by MR studies or meta-analyses of RCTs on supplementary 
micronutrients (ie, in vitamin D). This may be either due to 
differences in the study designs (observational study tests the 
presence of associations while MR study and RCT explore 
causality) or due to their inherent distinct limitations and bi-
ases. Conversely, four “likely noncausal” associations identi-
fied from MR studies also were reported as negative results 
by meta-analyses of observational studies, that is, selenium, 
total cholesterol, LDL-cholesterol, and telomere length.
5 |  STRENGTHS AND 
LIMITATIONS
This umbrella review presents for the first time, integrated 
evidence from meta-analyses of observational studies, MR 
studies, and RCTs with the aim to improve our understanding 
of the associations between non-genetic biomarkers and CRC 
risk. Each of the included studies have different strength and 
limitations and, if consistent, could strengthen our confidence 
in findings.45 The umbrella review design has a number of 
strengths as previously summarized.46-49 It also has several 
limitations. First, in an umbrella review, only systematic re-
views with meta-analyses and MR studies are included, thus 
associations with biomarkers that have not been included in 
meta-analyses are not evaluated (ie, circulation sex hormone 
levels).50,51 We did not search for pre-print articles which are 
not peer reviewed, and we have therefore not included stud-
ies of newly detected CRC-related biomarkers. Given that no 
meta-analyses of RCTs on biomarkers were identified, we 
included meta-analyses of RCTs on intake of micronutrients 
as proxies of micronutrient levels measured in blood. Along 
with the inclusion of MR studies, these might offset the ab-
sence of meta-analyses of RCTs. A note of caution though 
is the uncertain association between supplementary dose 
and physiological dose of micronutrients across participants. 
Second, there might have been heterogeneity of effects based 
on anatomical site,52 gender, body mass index, diabetes mel-
litus, and other risk factors,53 but we did not perform any 
subgroup analysis. Third, we did not evaluate the quality 
assessment of the component studies of each meta-analysis 
of observational studies (apart from meta-analyses classi-
fied as convincing or highly suggestive) and the eligibility 
of component studies depended on the authors of each meta-
analysis. Most of the included meta-analyses estimated the 
quality of the individual studies by applying the Newcastle-
Ottawa Scale, which has low reliability between independent 
reviewers.54 Fourth, the limitations of the adopted credibility 
assessment criteria have been described previously and also 
apply here.46-49 Finally, evidence from meta-analyses of ob-
servational studies could be biased by confounding factors or 
by reverse causality.
6 |  CONCLUSION
This umbrella review represents a comprehensive summary 
and evidence triangulation of a wide range of CRC risk-asso-
ciated non-genetic biomarkers. In conclusion, we report and 
classify the evidence for non-genetic biomarkers detected 
from meta-analyses of observational studies, MR studies, and 
meta-analyses of RCTs. Convincing evidence of a clear role 
of a non-genetic biomarker in CRC risk has not been detected 
from meta-analyses of observational studies. From MR stud-
ies, a likely causal increased CRC risk with arachidonic acid 
and a likely causal decreased risk with linoleic acid and oleic 
acid were suggested. Conversely, seven biomarkers (LDL-
cholesterol, n-6 PUFAs, total cholesterol, selenium, vitamin 
B12, telomere length, and adiponectin) are likely noncausal. 
Four (LDL-cholesterol, total cholesterol, selenium, and tel-
omere length) of these seven biomarkers have consistent 
results (likely noncausal) from MR and meta-analyses of ob-
servational studies.
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